why does nobody talk about 503A
why does nobody talk about 503A. I would rather ask a basic question now than get this wrong quietly for two months. Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality. The shortage list is the legal hinge: the…
Removed the staff name. Facilities and clinics can be named here; individuals cannot.
ask what the beyond-use date is based on
I would not read the price difference as a quality signal. Most of it is the consultation model, not the vial.
the shortage list is the whole legal hinge and people skip it
the shortage list is the whole legal hinge and people skip it
Agreed — and the follow-up question is what the beyond-use date is based on.
if a clinic will not name the facility, that is your answer
salt forms are the recurring argument and the answer is boring
What is the beyond-use date and what is it based on?
potency testing on the finished preparation is the thing to ask for
the pharmacy and the prescriber are two separate questions
the API source is the question nobody asks and everybody should
Agreed. The 503A versus 503B distinction changes who is allowed to make what, and almost every confused thread here starts by ignoring it.